In the webinar Winlow talks about the US P3 trials that were also successful. If those results were so successful why haven't the regulators legalised the supervised use of MDMA to treat PTSD in the US? We all know the major SP catalyst for biotechs is FDA approval, but there is no chance of that for at least 5 years according to Winlow. There is also no suggestion from other regulators that they will legalise MDMA use. My guess is that's why the share prices hasn't moved much off these good results.
EMD Price at posting:
3.7¢ Sentiment: Hold Disclosure: Held
